# Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants

> **NCT06830954** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 110 (estimated)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Group A
- **DRUG:** Reference Group

## Key facts

- **NCT ID:** NCT06830954
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06830954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06830954, "Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06830954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*